Workflow
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice

Core Viewpoint - Growth investors are increasingly focused on stocks with above-average financial growth, but identifying stocks that can sustain this growth is challenging [1] Group 1: Company Overview - BioMarin Pharmaceutical (BMRN) is highlighted as a recommended growth stock due to its favorable Growth Score and top Zacks Rank [2][10] Group 2: Earnings Growth - BioMarin has a historical EPS growth rate of 40.9%, with projected EPS growth of 23% this year, surpassing the industry average of 19.7% [5][4] Group 3: Cash Flow Growth - The year-over-year cash flow growth for BioMarin is 83.6%, significantly higher than the industry average of -4.7% [6] - The company's annualized cash flow growth rate over the past 3-5 years is 40.1%, compared to the industry average of 4.1% [7] Group 4: Earnings Estimate Revisions - Current-year earnings estimates for BioMarin have been revised upward, with the Zacks Consensus Estimate increasing by 0.1% over the past month [8] Group 5: Investment Potential - BioMarin has achieved a Growth Score of B and a Zacks Rank 1, indicating it is a potential outperformer and a solid choice for growth investors [10]